Yuri Ahuja

Yuri Ahuja

Auto-generated profile, based on publicly available information

Yuri Ahuja

Oatmeal Health, Mountain View, CA, USA; Icahn School of Medicine at Mount Sinai, New York, NY, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2022 in Journal of Biomedical Informatics
Verified
Journal Article
Open access
YAYuri Ahuja
Yuri Ahuja
YZYuesong Zou
Yuesong Zou
AVAman Verma
Aman Verma
DBDavid Buckeridge
David Buckeridge
YLYue Li
Yue Li
Electronic Health Records (EHRs) contain rich clinical data collected at the point of the care, and their increasing adoption offers exciting opportunities for clinical informatics, disease risk prediction, and personalized treatment recommendation. However, effective use of EHR data for research and clinical decision support is often hampered by a lack of reliable disease labels. To compile gold-standard labels, researchers often rely on clinical experts to develop rule-based phenotyping algorithms from billing codes and other surrogate features. This process is tedious and error-prone due to recall and observer biases in how codes and measures are selected, and some phenotypes are incompletely captured by a handful of surrogate features. To address this challenge, we present a novel automatic phenotyping model called MixEHR-Guided (MixEHR-G), a multimodal hierarchical Bayesian topic model that efficiently models the EHR generative process by identifying latent phenotype structure in the data. Unlike existing topic modeling algorithms wherein the inferred topics are not identifiable, MixEHR-G uses prior information from informative surrogate features to align topics with known phenotypes. We applied MixEHR-G to an openly-available EHR dataset of 38,597 intensive care patients (MIMIC-III) in Boston, USA and to administrative claims data for a population-based cohort (PopHR) of 1.3 million people in Quebec, Canada. Qualitatively, we demonstrate that MixEHR-G learns interpretable phenotypes and yields meaningful insights about phenotype similarities, comorbidities, and epidemiological associations. Quantitatively, MixEHR-G outperforms existing unsupervised phenotyping methods on a phenotype label annotation task, and it can accurately estimate relative phenotype prevalence functions without gold-standard phenotype information. Altogether, MixEHR-G is an important step towards building an interpretable and automated phenotyping system using EHR data.

1 August 2020 in Journal of the American Medical Informatics Association
Verified
Journal Article
Open access
PDF file
YAYuri Ahuja
Yuri Ahuja
DZDoudou Zhou
Doudou Zhou
ZHZeling He
Zeling He
JSJiehuan Sun
Jiehuan Sun
VCVictor M Castro
Victor M Castro
TCTianxi Cai
Tianxi Cai
Objective: A major bottleneck hindering utilization of electronic health record data for translational research is the lack of precise phenotype labels. Chart review as well as rule-based and supervised phenotyping approaches require laborious expert input, hampering applicability to studies that require many phenotypes to be defined and labeled de novo. Though International Classification of Diseases codes are often used as surrogates for true labels in this setting, these sometimes suffer from poor specificity. We propose a fully automated topic modeling algorithm to simultaneously annotate multiple phenotypes. Materials and Methods: Surrogate-guided ensemble latent Dirichlet allocation (sureLDA) is a label-free multidimensional phenotyping method. It first uses the PheNorm algorithm to initialize probabilities based on 2 surrogate features for each target phenotype, and then leverages these probabilities to constrain the LDA topic model to generate phenotype-specific topics. Finally, it combines phenotype-feature counts with surrogates via clustering ensemble to yield final phenotype probabilities. Results: sureLDA achieves reliably high accuracy and precision across a range of simulated and real-world phenotypes. Its performance is robust to phenotype prevalence and relative informativeness of surogate vs nonsurrogate features. It also exhibits powerful feature selection properties. Discussion: sureLDA combines attractive properties of PheNorm and LDA to achieve high accuracy and precision robust to diverse phenotype characteristics. It offers particular improvement for phenotypes insufficiently captured by a few surrogate features. Moreover, sureLDA’s feature selection ability enables it to handle high feature dimensions and produce interpretable computational phenotypes. Conclusions: sureLDA is well suited toward large-scale electronic health record phenotyping for highly multiphenotype applications such as phenome-wide association studies .

22 October 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YAYuri Ahuja
Yuri Ahuja
JWJun Wen
Jun Wen
CHChuan Hong
Chuan Hong
ZXZongqi Xia
Zongqi Xia
SHSicong Huang
Sicong Huang
TCTianxi Cai
Tianxi Cai
While there exist numerous methods to identify binary phenotypes (i.e. COPD) using electronic health record (EHR) data, few exist to ascertain the timings of phenotype events (i.e. COPD onset or exacerbations). Estimating event times could enable more powerful use of EHR data for longitudinal risk modeling, including survival analysis. Here we introduce Semi-supervised Adaptive Markov Gaussian Embedding Process (SAMGEP), a semi-supervised machine learning algorithm to estimate phenotype event times using EHR data with limited observed labels, which require resource-intensive chart review to obtain. SAMGEP models latent phenotype states as a binary Markov process, and it employs an adaptive weighting strategy to map timestamped EHR features to an embedding function that it models as a state-dependent Gaussian process. SAMGEP’s feature weighting achieves meaningful feature selection, and its predictions significantly improve AUCs and F1 scores over existing approaches in diverse simulations and real-world settings. It is particularly adept at predicting cumulative risk and event counting process functions, and is robust to diverse generative model parameters. Moreover, it achieves high accuracy with few (50–100) labels, efficiently leveraging unlabeled EHR data to maximize information gain from costly-to-obtain event time labels. SAMGEP can be used to estimate accurate phenotype state functions for risk modeling research.

9 March 2021 in medRxiv
Verified
Preprint
Open access
PDF file
YAYuri Ahuja
Yuri Ahuja
CHChuan Hong
Chuan Hong
ZXZongqi Xia
Zongqi Xia
TCTianxi Cai
Tianxi Cai
Objective While there exist numerous methods to predict binary phenotypes using electronic health record (EHR) data, few exist for prediction of phenotype event times, or equivalently phenotype state progression. Estimating such quantities could enable more powerful use of EHR data for temporal analyses such as survival and disease progression. We propose Semi-supervised Adaptive Markov Gaussian Embedding Process (SAMGEP), a semi-supervised machine learning algorithm to predict phenotype event times using EHR data. Methods SAMGEP broadly consists of four steps: (i) assemble time-evolving EHR features predictive of the target phenotype event, (ii) optimize weights for combining raw features and feature embeddings into dense patient-timepoint embeddings, (iii) fit supervised and semi-supervised Markov Gaussian Process models to this embedding progression to predict marginal phenotype probabilities at each timepoint, and (iv) take a weighted average of these supervised and semi-supervised predictions. SAMGEP models latent phenotype states as a binary Markov process, conditional on which patient-timepoint embeddings are assumed to follow a Gaussian Process. Results SAMGEP achieves significantly improved AUCs and F1 scores relative to common machine learning approaches in both simulations and a real-world task using EHR data to predict multiple sclerosis relapse. It is particularly adept at predicting a patient’s longitudinal phenotype course, which can be used to estimate population-level cumulative probability and count process estimators. Reassuringly, it is robust to a variety of generative model parameters. Discussion SAMGEP’s event time predictions can be used to estimate accurate phenotype progression curves for use in downstream temporal analyses, such as a survival study for comparative effectiveness research.

15 February 2022 in Biostatistics
Verified
Journal Article
Closed access
PDF file
YAYuri Ahuja
Yuri Ahuja
LLLiang Liang
Liang Liang
DZDoudou Zhou
Doudou Zhou
SHSicong Huang
Sicong Huang
TCTianxi Cai
Tianxi Cai
Summary: Leveraging large-scale electronic health record (EHR) data to estimate survival curves for clinical events can enable more powerful risk estimation and comparative effectiveness research. However, use of EHR data is hindered by a lack of direct event time observations. Occurrence times of relevant diagnostic codes or target disease mentions in clinical notes are at best a good approximation of the true disease onset time. On the other hand, extracting precise information on the exact event time requires laborious manual chart review and is sometimes altogether infeasible due to a lack of detailed documentation. Current status labels—binary indicators of phenotype status during follow-up—are significantly more efficient and feasible to compile, enabling more precise survival curve estimation given limited resources. Existing survival analysis methods using current status labels focus almost entirely on supervised estimation, and naive incorporation of unlabeled data into these methods may lead to biased estimates. In this article, we propose Semisupervised Calibration of Risk with Noisy Event Times (SCORNET), which yields a consistent and efficient survival function estimator by leveraging a small set of current status labels and a large set of informative features. In addition to providing theoretical justification of SCORNET, we demonstrate in both simulation and real-world EHR settings that SCORNET achieves efficiency akin to the parametric Weibull regression model, while also exhibiting semi-nonparametric flexibility and relatively low empirical bias in a variety of generative settings.

21 September 2017 in Cell Cycle
Verified
Journal Article
Open access
CMChanatip Metheetrairut
Chanatip Metheetrairut
YAYuri Ahuja
Yuri Ahuja
FSFrank J. Slack
Frank J. Slack
The heterochronic pathway in C. elegans controls the relative timing of cell fate decisions during post-embryonic development. It includes a network of microRNAs (miRNAs), such as let-7, and protein-coding genes, such as the stemness factors, LIN-28 and LIN-41. Here we identified the acn-1 gene, a homologue of mammalian angiotensin-converting enzyme (ACE), as a new suppressor of the stem cell developmental defects of let-7 mutants. Since acn-1 null mutants die during early larval development, we used RNAi to characterize the role of acn-1 in C. elegans seam cell development, and determined its interaction with heterochronic factors, including let-7 and its downstream interactors – lin-41, hbl-1, and apl-1. We demonstrate that although RNAi knockdown of acn-1 is insufficient to cause heterochronic defects on its own, loss of acn-1 suppresses the retarded phenotypes of let-7 mutants and enhances the precocious phenotypes of hbl-1, though not lin-41, mutants. Conversely, the pattern of acn-1 expression, which oscillates during larval development, is disrupted by lin-41 mutants but not by hbl-1 mutants. Finally, we show that acn-1(RNAi) enhances the let-7-suppressing phenotypes caused by loss of apl-1, a homologue of the Alzheimer's disease-causing amyloid precursor protein (APP), while significantly disrupting the expression of apl-1 during the L4 larval stage. In conclusion, acn-1 interacts with heterochronic genes and appears to function downstream of let-7 and its target genes, including lin-41 and apl-1.